GMEB-SASS: A Gene-Modified Skin Substitute for RDEB Treatment

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

RDEB · Recessive Dystrophic Epidermolysis Bullosa · Epidermolysis Bullosa Dystrophica, Recessive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The Hospital for Sick Children (SickKids), Toronto, Ontario, Canada
Contact: Study coordinator (Hanna Fadzeyeva) · hanna.fadzeyeva@sickkids.ca · 416-813-7835
Contact: Study coordinator (Pope Elena, MD, FRCPC) · Elena.Pope@sickkids.ca · 416-813-6883
Contact: Principal Investigator (Elena Pope, MD, FRCPC)

Study leads

Lucie Germain, PhD
Study Director
CHU de Québec-Université Laval
Elena Pope, MD, FRCPC
Principal Investigator
The Hospital for Sick Children

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa · Epidermolysis Bullosa Acquisita · Dystrophic Epidermolysis Bullosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Redwood City, United States

MSC EVs in Dystrophic Epidermolysis Bullosa

Dystrophic Epidermolysis Bullosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Los Angeles, United States

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

Recessive Dystrophic Epidermolysis Bullosa

Abroad (travel likely)Recruiting

Palo Alto, United States · Aurora, United States

Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica

Abroad (travel likely)Recruiting

Stanford, United States